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Abstract
Background—A severe flare of colitis in patients with IBD treated with immunosuppressive
therapy may be complicated by an underlying CMV infection. The aim of this pilot study was to
investigate the diagnostic efficacy of quantitative polymerase chain reaction (PCR) to detect CMV
DNA in stool samples of IBD patients.
Methods—Twenty-one patients with a severe flare of IBD, incompletely responding or refractory
to either steroids or immunosuppressive agents, were included in the study. Nineteen patients
completed the study according to the protocol undergoing an endoscopy with biopsies and collection
of stool samples. Biopsy and stool samples were qualitatively and quantitatively analyzed for CMV
DNA using real-time PCR.
Results—Thirty-two percent (6/19) of the patients had detectable CMV DNA in colonic biopsies
and in five (83%) of those patients CMV DNA was detected in the stool. Thirteen patients had
negative findings for CMV DNA in biopsy and stool samples. The sensitivity, specificity, and
accuracy of the PCR-based stool test for detection of CMV DNA compared to PCR-based detection
of CMV in mucosal biopsies were 83, 93, and 90%, respectively.
Conclusions—The pilot study suggests a high accuracy of this non-invasive testing method to
detect CMV DNA in stool samples as compared to mucosal biopsies. This approach may offer a non-
endoscopic testing modality for underlying CMV infection in patients with a severe flare of IBD,
Correspondence to: Hans H. Herfarth, hherf@med.unc.edu.
NIH Public Access
Author Manuscript
Dig Dis Sci. Author manuscript; available in PMC 2011 April 1.
Published in final edited form as:













which could also be applied more broadly to determine the prevalence of CMV infections in patients
with IBD.
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Introduction
Cytomegalovirus (CMV), a member of the herpesvirus family, is a well-known cause of
gastrointestinal pathology in immunocompromised patients, whereas gastrointestinal
symptoms in an immunocompetent host are rarely observed [1]. Classically, CMV enterocolitis
with large ulcerations visible on upper or lower GI-endoscopy can be observed during CMV
viremia in HIV patients and organ transplant patients [2]. A number of reports suggest that
CMV infection may be an underlying factor in patients with severe colitis refractory to
intravenous steroids and/or immunosuppressive therapy (e.g., cyclosporine) [3–14]. CMV
infection is common in the general population with a reported seroprevalence of 40–100%
[15]. Therefore, latency of the virus and reactivation during exacerbation of the colitis in
patients with IBD is probably the most common cause of detected CMV infection. The
prevalence of CMV IgG in patients with ulcerative colitis (UC) was recently described as 70%
and a reactivation of CMV detected by CMV antigenemia and plasma quantitative PCR
occurred in more than 50% of ulcerative colitis (UC) patients while being treated with steroids
or immunosuppressive drugs [12].
With the exception of retinitis, a CMV infection cannot be diagnosed alone using clinical skills.
Also, no standardized recommendations exist on how best to diagnose a concurrent CMV
infection in the setting of colitis or how to interpret positive or negative findings. Several
techniques are available for diagnosing CMV colitis with each one having advantages and
disadvantages. CMV infection of the colon can be diagnosed using histology
(hematoxylineosin staining) or immunohistochemistry [16], which is considered a gold
standard, but due to sampling error may also yield false-negative results. Serology is very
limited in detecting active CMV infection, since anti-CMV IgM antibody levels can persist up
to 2 years after infection and immunocompromised patients may not mount an IgM response.
CMV culture can be performed on a whole variety of body fluids and tissue, but has the
disadvantage of long incubation times and a relative low sensitivity [17]. The CMV antigen
test detects the internal matrix protein pp65 in circulating leukocytes but the technique is only
semiquantitative and less sensitive as compared to CMV PCR [18], which is currently the most
sensitive test for detecting systemic CMV infection in plasma or serum samples [17]. PCR has
been also applied for the amplification of CMV DNA from mucosal biopsies [19,20].
During active CMV infection, CMV viral shedding occurs in the urine, respiratory secretions,
and stool of infected patients [21,22]. The analysis of these shed viral particles in
bronchoalveolar secretions may increase the sensitivity for the detection of an underlying CMV
infection as shown in patients with suspected CMV pneumonitis [23,24]. Qualitative and/or
quantitative stool CMV DNA testing by PCR is a noninvasive technique [22,25] and may offer
the possibility to test for a concurrent CMV infection in patients with refractory IBD without
the need for obtaining endoscopic biopsies. Therefore, our aim was to evaluate the sensitivity,
specificity, accuracy, and feasibility of the detection of CMV DNA in stool samples compared
to the detection of CMV DNA in intestinal biopsies from patients with a severe flare of IBD
and suspicion of associated CMV-colitis or CMV-enteritis.
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The prospective study was conducted at the University of North Carolina from July 2007 until
November 2008. The local Institutional Review Board (IRB) approved the study. All patients
included in the study had been hospitalized due to an exacerbation of a previously proven
inflammatory bowel disease (Crohn's disease or ulcerative colitis), and underwent a
sigmoidoscopy or colonoscopy with biopsies for histology and qualitative CMV-PCR. The
biopsies were taken in the rectosigmoid colon or in case of patients with ileostoma (one patient)
in the distal ileum (two biopsies for pathological evaluation, one biopsy for PCR). Clinical
follow-up was performed by chart review for 6 months after inclusion in the study.
All biopsies were evaluated by a pathologist, who was not aware of the PCR results of the
biopsies or plasma using a regular hematoxylin and eosin (H&E) stain. Large cells containing
a basophilic intranuclear inclusion were regarded as diagnostic of CMV infection. At the
discretion of the pathologist immunohistochemistry stains were also performed on formalin-
fixed and paraffin-embedded tissue using standard immunohistochemical techniques
(antibody: DAKO clone CCH2 and DDG9) following a citrate-based epitope antigen retrieval
step.
One stool sample of each participating patient was collected in a time period of 12 h after the
endoscopic procedure (see Fig. 1). At the discretion of the treating physician, plasma samples
for the detection of circulating CMV DNA were also drawn in 16 patients. The stool samples
were freshly collected (approx. 1.5 g) and immediately placed and homogenized in a conical
tube containing 5 ml of STAR buffer (Stool Transport and Recovery buffer, Roche
Diagnostics); chloroform (500 μl) was added and the sample was centrifuged (1 min at 3,300
rpm). Total nucleic acids (TNA) were isolated from the supernatant using MagNA Pure LC
(Roche Diagnostics). TNA from the colonic biopsies were extracted from 200 μl of viral
transport medium in which the colonic biopsies had been ground and/or from 200 μl plasma
using the Roche MagNAPure LC according to the manufacturer's instructions. The elution
volume was 50 μl.
CMV PCR Assay
The detection of CMV DNA in plasma, biopsies, and stool samples was performed using real-
time PCR and previously described primers and TaqMan probe that target the CMV polymerase
I gene [26]. The internal control targets were the human albumin gene (qualitative) and TaqMan
Exogeneous Internal Positive Control (quantitative; Applied Biosystems, Foster City, CA).
The internal control was detected separately for the qualitative assay but as a multiplex in the
quantitative assay. The 50-μl reaction mixture contained TaqMan Universal PCR Master Mix
(Applied Biosystems), 900-nM (qualitative) or 250-nM (quantitative) primers and 200-nM
(qualitative) or 250-nM (quantitative) probe. PCR cycling parameters were 2 min of incubation
at 50°C and 10 min at 95°C, followed by 45 cycles of 95°C for 15 s and 60°C for 1 min. For
the quantitative PCR, a standard curve of CMV Towne strain DNA was assayed. The limit of
detection for the qualitative assay is 200 copies/ml and the limit of quantification is 500 copies/
ml.
Statistical Analysis
Using endoscopically retrieved mucosal biopsies for PCR-amplification of CMV as the gold
standard for diagnosis of active CMV infection, the sensitivity and specificity of stool-based
PCR CMV DNA test for the diagnosis of CMV were calculated. The accuracy, defined as total
correctly classified over total in population, was also calculated. Finally, the positive predictive
value of the test, the probability that the patient has the disease given that a positive test has
been obtained, and the negative predictive value (inverse of above) were also calculated.
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Twenty-one patients were included in the prospective study and signed the informed consent
(Fig. 1). Two of the 21 patients underwent endoscopy, but were not able to provide a stool
sample within the study time window of 12 h after sigmoidoscopy and were excluded from
further analysis. Two patients were tested twice in the time frame of the study. Therefore, a
total 21 stool samples and 21 biopsies from 19 patients were analyzed for CMV DNA. The
patient characteristics and concurrent therapies are described in Table 1. A total of 84% of the
patients were either treated with oral or intravenous steroids, 26% with azathioprine/6-MP,
10% with methotrexate, and 21% with an anti-TNF agent.
CMV DNA Detection in Colonic Biopsies, Stool, and Plasma Specimens
CMV DNA could be amplified by PCR in colonic biopsies (CMVB×PCR+) in 6/19 patients
(32%; six biopsies), whereas in 13 patients (15 biopsies) CMV DNA was not detectable in the
biopsies (CMVB×PCR−). In 83% (5/6) of the CMVB×PCR+ biopsies either typical
histological or immunohistochemical characteristics suggestive of a CMV infection were
described by the pathologist.
Two of the 21 stool samples solidified before analysis and the homogenization of the sample
in the buffer to extract the viral DNA was technically not possible (in one case the patient was
CMVB×PCR+, in the other case the patient was CMVB×PCR−, see Table 2). For the analysis
of the sensitivity and specificity of the PCR-based stool test we considered these samples as
false-negative and false-positive (Table 3). A total of 5/6 (83%) CMVB×PCR+ cases also had
detectable CMV in the corresponding stool sample and 14/15 (93%) CMVB×PCR− cases had
no detectable CMV DNA in the corresponding stool sample. The sensitivity and specificity of
the stool test compared to PCR of mucosal biopsies were 83 and 93%, respectively. The positive
and negative predictive values of the stool-based PCR test for CMV disease were 83 and 93%,
respectively (see Table 3). The accuracy of the test was 19/21 or 90%.
The detection of systemic CMV DNA by evaluation of plasma by PCR was performed outside
the study protocol at the discretion of the treating physician. In 16/21 (76%) of the cases, plasma
samples were also obtained. In 67% (4/6) of the CMVB×PCR+ cases plasma CMV DNA could
be amplified by PCR, whereas in one case CMV DNA was not detected and in the other case
the test was not performed (see Table 2). In the 15 CMVB×PCR− cases, ten analyses of plasma
for CMV DNA were performed. In each case, CMV DNA could not be amplified in the plasma.
Clinical Outcome
All six patients with positive CMV biopsy results were treated with oral valganciclovir. Two
patients with CMVB×PCR+ UC underwent colectomy due to refractory disease 8 and 9 days
after the inclusion in the study, whereas the other three CMVB×PCR+ UC and one
CMVB×PCR+ CD patient responded to valganciclovir therapy. However, all three UC patients
finally underwent colectomy due to therapy refractory disease after 2.5–5 months. Histology
specimen of the colectomy preparations did not reveal active CMV colitis at the time point of
resection in any of the cases. Also, 3/13 patients (n = 2 with UC, n = 1 with Crohn's colitis) in
the CMV-negative group underwent colectomy 6, 10, and 30 days, respectively, after inclusion
in the study.
Discussion
The first case report about a young patient with active UC and a concurrent severe CMV colitis
necessitating colectomy at the University of Chicago was reported in 1961 [27]. Since then,
numerous other reports and case series have been published. It is currently thought that between
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20 and 35% of patients with severe colitis due to IBD, who are either refractory to steroids or
to immunosuppressive medications such as cyclosporine, tacrolimus, or an anti-TNF agent,
may also suffer from an underlying CMV-enteritis [4,8,28,29]. Multiple techniques are
employed to diagnose a concurrent intestinal CMV infection in IBD patients and so far no firm
recommendations for the best approach have been established [30–32]. However, the detection
of CMV DNA by PCR analysis in mucosal biopsies has been described as the most sensitive
method in patients with suspected CMV-enteritis [20,30,33].
In this prospective study, we included patients with active IBD not fully responsive or
refractory to either steroids and/or other immunosuppressive medications. Thirty-two
percentage of these patients had detectable CMV DNA by PCR in colonic biopsies. We
demonstrate that fresh stool qualitative and qualitative PCR for CMV is a method with similar
sensitivity and specificity to endoscopic collection of mucosal biopsies for PCR amplification
of CMV DNA. This is in line with a recent report indicating similar sensitivities and
specificities for CMV DNA in stool samples of HIV-infected patients [22]. This report also
suggested a high negative predictive value for a concurrent intestinal CMV infection if no
CMV shedding could be detected by PCR in the stool sample. In our study, the negative
predictive value for a concurrent intestinal CMV infection was 93%. This slightly suboptimal
value was due to the fact that we also included patients in the study, who provided stool samples,
which solidified shortly after collection, thus excluding these samples from further analysis.
We decided not to exclude these samples from the sensitivity and specificity analysis, since
we wanted to examine the test given “real-life” conditions. If we had included only stool
samples, which could be analyzed for CMV particles by PCR, the positive and negative
predictive value of the test would have been 100%.
Histological signs of CMV infection were found on H&E stains (inclusion bodies) or by
immunohistochemistry in 83% of the patients (5/6), who were tested positive for CMV DNA
by PCR in the stool. One patient with an endoscopic picture highly suggestive of CMV colitis
who tested positive for CMV DNA in colonic biopsy and plasma, showed no signs of CMV
infection either by H&E stain or by immunohistochemistry. This supports the higher sensitivity
of the PCR-based diagnostic approach for the diagnosis of CMV colitis. Additionally we
detected CMV DNA in the plasma of 83% of the patients with detectable CMV DNA in the
mucosal biopsies. We also observed higher CMV DNA levels in the fecal samples compared
to the biopsy and plasma samples. Similar findings have been reported previously [25]. It is
not clear whether CMV DNA detected in the stool samples in this study was due to leakage
from the blood compartment into the intestinal tract, or if it was derived from intestinal CMV
infection. Additionally we would like to point out that currently no specific cut-off levels for
the amplified number of CMV virus particles in biopsies or stool are defined indicating, e.g.,
different histological or clinical severities of a colonic CMV infection. Also, this pilot trial was
not designed to compare the multiple different methods for CMV detection such as histology,
immunohistochemistry, CMV-pp65 antigen assay, CMV-plasma and biopsy PCR, CMV
serology or CMV culture, which has been done in other trials [28,34]. Another limitation of
the present pilot study includes the small number of patients with biopsy-proven CMV colitis.
Larger studies also investigating the above-mentioned diagnostic modalities would be of
interest.
A total of 40% of the patients with severe colitis and underlying CMV infection underwent
colectomy shortly (8 and 9 days) after the additional diagnosis of the CMV infection despite
valgancyclovir therapy. In contrast, the colectomy rate in the CMV-negative group was 23%
in a time period of 4 weeks after inclusion. The remaining three UC patients with positive CMV
DNA PCR first improved with valgancyclovir therapy but underwent a colectomy later on due
to refractory disease. The higher likelihood of colectomy due to an underlying CMV-colitis
despite antiviral therapy in patients with refractory UC has been demonstrated in the past,
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however, individual predictive risk factors for non-responsiveness to antiviral therapy and
colectomy as well as a strict causality of CMV infection as an only reason for disease
deterioration could not yet be determined [29]. In our case series, the resected specimen of all
of the patients showed no signs of active CMV infection as assessed by histology ruling out
continuing fulminant CMV infection despite valgancyclovir therapy. There was also no
association between the amount of CMV-copies in the colonic biopsies, in the stool or plasma
samples and the time point of colectomy. Only the CD patient with CMV enteritis, proven not
only by PCR, but also by immunohistochemistry, slowly improved after the valgancyclovir
therapy, but also had prolonged symptoms of disease activity and was found to have sustained
small-bowel ulcerations on a repeated endoscopy. The symptoms and ulcerations improved
after the patient was started on an anti-TNF agent. The anti-TNF therapy was only started after
a repeat endoscopy ruled out recurrent CMV enteritis. Recent reports also indicate, that it might
be safe to start patients with diagnosed CMV colitis on anti-TNF agents [35,36].
There are several advantages of detecting CMV DNA in fresh stool specimen by PCR. This is
a fast, cheap, and uncomplicated procedure, which only involves the collection of a fresh stool
specimen. Additionally, it does not involve invasive procedures such as a sigmoidoscopy or
colonoscopy to obtain the biopsies necessary for the PCR analysis, which makes this diagnostic
approach especially valuable in an outpatient setting. Moreover, since many patients with
severe colitis often only undergo a sigmoidoscopy for obtaining the biopsies, the approach of
detecting shed CMV viral particles in the stool could theoretically also reveal a CMV infection
only limited to the right colon, small bowel, or upper GI tract.
A potential drawback of the method is the need for a fresh and liquid stool specimen. If the
stool specimen cannot be homogenized due to solidification or if the stool is solid, DNA cannot
be reliably extracted from the stool specimen. This is illustrated by the fact that homogenization
of the stool specimen in two of our patients was not possible due to solidification of the sample.
The collection and fast extraction of DNA from the stool specimen using a stabilizing buffer
is also necessary to prevent DNA degradation.
In summary, this pilot study suggests a high sensitivity, specificity, and accuracy for the
detection of CMV DNA in stool samples compared to mucosal biopsies using PCR. This non-
invasive diagnostic method offers a fast testing protocol in the clinical in- and outpatient setting
and might also present a new modality to broadly analyze the prevalence of intestinal CMV
infections in IBD patients.
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Flow diagram of the study
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Table 1
Patient demographics
Patients (n; M/F) 10/9
Age (years) median (range) 34 (20–65)
Diagnosis UC/CD 11/8a
Therapy (n)





One patient with ileostomy due to CD had a history of colectomy due to severe colitis. All other seven CD patients had severe Crohn's colitis
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Table 2
CMV DNA copy number in biopsy, stool and plasma specimen in six different study patients
Case number Dx CMV PCR biopsy copies/ml CMV PCR stool copies/ml CMV plasma copies/ml
2 UC <500 2,316 <500
4 UC <500 40,317 <500
5 UC 1,826 40,339 Negative
9 UC 117,775 NDb 6,252
18 CDa 91,125 2,266 ND
23 UC 834 19,672 <500
In the other 13 study patients CMV PCR of 15 biopsies and stool samples were all negative for CMV DNA
ND, not done
a
Patient with ileostomy due to CD with a history of colectomy due to severe colitis
b
Determination of CMV DNA technical not possible due to solidification of stool sample prior to homogenization for DNA extraction
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Table 3
2 × 2 table demonstrating the positive or negative findings for CMV DNA based on qualitative PCR in 21 mucosal
biopsies and stool samples of 19 patients
CMV DNA in mucosal biopsies
+ -
CMV DNA in stool samples + 5 1 6
- 1 14 15
6 15
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